Abstract

http://ssrn.com/abstract=838545
 
 

Citations (2)



 
 

Footnotes (20)



 


 



Assessing the Safety and Efficacy of the Fda: The Case of the Prescription Drug User Fee Acts


Tomas Philipson


University of Chicago; National Bureau of Economic Research (NBER)

Ernst R. Berndt


Massachusetts Institute of Technology (MIT) - Sloan School of Management; National Bureau of Economic Research (NBER)

Adrian Gottschalk


Biogen Idec, Inc.

Matthew W. Strobeck


affiliation not provided to SSRN

October 2005

NBER Working Paper No. w11724

Abstract:     
The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about $11 to $13 billion. Dependent on the market power assumed of producers while having patent protection, we find that PDUFA raised consumer welfare between $5 to$19 billion; thus the combined social surplus was raised between $18 to $31 billions. Converting these economic gains into equivalent health benefits, we find that the more rapid access of drugs on the market enabled by PDUFA saved the equivalent of 180 to 310 thousand life-years. Additionally, we estimate an upper bound on the adverse effects of PDUFA based on drugs submitted during PDUFA I/II and subsequently withdrawn for safety reasons, and find that an extreme upper bound of about 56 thousand life-years were lost. We discuss how our general methodology could be used to perform a quantitative and evidence-based evaluation of the desirability of other FDA policies in the future, particularly those affecting the speed-safety tradeoff.

Number of Pages in PDF File: 42

working papers series


Download This Paper

Date posted: January 19, 2006  

Suggested Citation

Philipson, Tomas and Berndt, Ernst R. and Gottschalk, Adrian and Strobeck, Matthew W., Assessing the Safety and Efficacy of the Fda: The Case of the Prescription Drug User Fee Acts (October 2005). NBER Working Paper No. w11724. Available at SSRN: http://ssrn.com/abstract=838545

Contact Information

Tomas J. Philipson (Contact Author)
University of Chicago ( email )
Graduate School of Business
1101 East 58th Street
Chicago, 60637
National Bureau of Economic Research (NBER)
1050 Massachusetts Avenue
Cambridge, MA 02138
United States
Ernst R. Berndt
Massachusetts Institute of Technology (MIT) - Sloan School of Management ( email )
Room E52-452
Cambridge, MA 02142
United States
617-253-2665 (Phone)
617-258-6055 (Fax)
National Bureau of Economic Research (NBER)
1050 Massachusetts Avenue
Cambridge, MA 02138
United States
Adrian Gottschalk
Biogen Idec, Inc.
14 Cambridge Center
Cambridge, MA 02142
United States
Matthew W. Strobeck
affiliation not provided to SSRN
No Address Available
Feedback to SSRN


Paper statistics
Abstract Views: 809
Downloads: 83
Download Rank: 178,234
Citations:  2
Footnotes:  20

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo8 in 0.250 seconds